COVID-19 associated pulmonary aspergillosis-an unusual manifestation of COVID-19

Authors

  • B. Anusuya Department of Pharmacy Practice, C. L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India
  • J. Yamini Department of Pharmacy Practice, C. L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20231456

Keywords:

COVID-19, CAPA, Pulmonary aspergillosis, Posaconazole

Abstract

A recently identified condition known as COVID-19-associated pulmonary aspergillosis (CAPA) is connected to the COVID-19 pandemic and is known as post-COVID complications. More data are awaited, and a consensus criterion was recently published in an effort to spur more research and registries to assist clinical decision-making. However, it is evident that CAPA imposes a COVID-19 illness course that worsens with increased morbidity and mortality. Here we present the case of a 53-year-old male patient admitted to our hospital after recovering from COVID-19. Due to his clinical condition, some investigation criteria were performed and Aspergillus fumigatus was identified in his culture test. Treatment was provided with posaconazole as a first-line drug, and the patient showed a good clinical outcome.

Metrics

Metrics Loading ...

References

Barber RM, Sorensen RJD, Pigott DM, Bisignano C, Carter A, Amlag JO, et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through: a statistical analysis. Lancet. 2022;399(10344):2351-80.

Kakamad FH, Mahmood SO, Rahim HM, Abdulla BA, Abdullah HO, Othman S, et al. Post covid-19 invasive pulmonary Aspergillosis: A case report. Int J Surg Case Rep. 2021;82:105865.

Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi (Basel). 2020;6(2):91.

Dimopoulos G, Almyroudi M-P, Myrianthefs P, Rello J. COVID-19-associated pulmonary aspergillosis (CAPA). J Intens Med. 2021;1(2):71-80.

Bhopalwala H, Mishra V, Do TV, Gudipati M, Ganti SS. COVID-19 infection and late manifestation of pulmonary aspergillosis. J Investig Med High Impact Case Rep. 2022;10:23247096211063332.

Intra J, Sarto C, Beck E, Tiberti N, Leoni V, Brambilla P. Bacterial and fungal colonization of the respiratory tract in COVID-19 patients should not be neglected. Am J Infect Control. 2020;48(9):1130-1.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1-60.

Armstrong-James D, Youngs J, Bicanic T. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur Respir J. 2020;56:2002554.

Downloads

Published

2023-05-25

How to Cite

Anusuya, B., & Yamini, J. (2023). COVID-19 associated pulmonary aspergillosis-an unusual manifestation of COVID-19. International Journal of Advances in Medicine, 10(6), 475–477. https://doi.org/10.18203/2349-3933.ijam20231456

Issue

Section

Case Reports